AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29193478
Drug: Carvacrol capsule
DrugBank: Carvacrol (DB16404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvacrol capsule (1.2 mg/kg/day) for 2 months
Trial: 20451896
Drug: Ahmed valve
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ahmed valve implant (model FP7; 184 mm² surface area)
Trial: 20451896
Drug: Molteno single-plate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molteno single-plate implant (134 mm² surface area)
Trial: 18630765
Drug: levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 0.25% 10 mL epidurally
Trial: 18630765
Drug: piritramide 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piritramide 0.08 mg kg(‐1) i.v.
Trial: 9045347
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of carboplatin and paclitaxel
Trial: 7590485
Drug: Intraperitoneal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal therapy
Trial: 15839958
Drug: Maintenance/consolidation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance/consolidation therapy
Trial: 15839958
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of a third non-cross-resistant drug to carboplatin and paclitaxel
Trial: 11886010
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) treatment
Trial: 9987087
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg FU plus a sham infusion
Trial: 9987087
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg FU plus 200 ml of a 20% solution of HA
Trial: 9987087
Drug: Sham infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham infusion plus 200 ml of a 20% solution of HA
Trial: 7027893
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 12.5 mg (group A) b.i.d for 12 weeks
Trial: 7027893
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 25 mg (group B) b.i.d for 12 weeks
Trial: 7027893
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose combination of hydrochlorothiazide with metoprolol
Trial: 30381901
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (approximately 25 g of protein from 125 g per week of sardine, advised to restrict carbohydrate intake)
Trial: 27853891
Drug: Ginsenoside Rb1
RxNorm normalized name: Ginsenoside Rb1
DrugBank: Ginsenoside Rb1 (DB06749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenoside Rb1 (500 mg daily oral administration, n = 103)
Trial: 24422876
Drug: Manual therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy-based physiotherapy intervention (C)
Trial: 14702492
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (aimed at providing 1800 mg of Ca/day)
Trial: 11720117
Drug: Nottingham Extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nottingham Extended Activities of Daily Living Scale (NEADL)
Trial: 9204354
Drug: Iopromide (Ultravist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopromide (Ultravist 300 mg I/ml)
Trial: 3610514
Drug: 0.1% benzydamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% benzydamine solution
Trial: 3610514
Drug: povidone-iodine vaginal
RxNorm normalized name: povidone-iodine Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: povidone-iodine vaginal suppositories
Trial: 3610514
Drug: 0.2% aluminium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% aluminium acetate solution
Trial: 29042177
Drug: Any change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any change in antibiotic exposure
Trial: 27827949
Drug: Hypoxia +
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxia + carbohydrate supplementation (6% carbohydrate solution, maltodextrin)
Trial: 30857448
Drug: Oral squamous
RxNorm normalized name: Vespula squamosa venom protein
DrugBank: Vespula squamosa venom protein (DB11032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral squamous cell carcinoma (OSCC) patients
Trial: 18023439
Drug: Triptorelin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (0.2 mg SC) in addition to hCG (5,000 U) 34 hours before oocyte aspiration
Trial: 1433581
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with prophylactic antibacterials
Trial: 4080137
Drug: High anxiety
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High anxiety treatment group
Trial: 4080137
Drug: Low anxiety
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low anxiety treatment group
Trial: 29435364
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg and 75 mg
Trial: 20672296
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg aztreonam for inhalation solution (AZLI) administered two (BID) or three times daily (TID) for up to nine courses (28 days on/28 days off)
Trial: 20672296
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg aztreonam for inhalation solution (AZLI) administered two (BID) or three times daily (TID)
Trial: 8032546
Drug: 0.9 MIU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 MIU/m2 IL-2 administered subcutaneously once weekly (4 doses, stratum I)
Trial: 8032546
Drug: 0.9 MIU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 MIU/m2 IL-2 administered subcutaneously three times a week every other day (9 doses, stratum II)
Trial: 8032546
Drug: 0.9 MIU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 MIU/m2 IL-2 administered subcutaneously five times a week every other week (10 doses, stratum III)
Trial: 1091171
Drug: Oral colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral colistin sulfate (non-absorbable broad-spectrum antimicrobial)
Trial: 23356250
Drug: Lime juice
RxNorm normalized name: lime juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lime juice treatment
Trial: 2189276
Drug: Ankerplast Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ankerplast Spray
Trial: 2189276
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Ankerplast Spray)
Trial: 30742122
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy alone
Trial: 24078483
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group received LLLT using a 'TOPHAT655' unit with 21 lasers (5 mW, 655 ± 5 nm) and 30 LEDs (655 ± 20 nm), treated at home every other day for 16 weeks (60 treatments).
Trial: 24078483
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group received a unit with incandescent red lights, treated at home every other day for 16 weeks (60 treatments).
Trial: 19664320
Drug: Cognitive-behavioural group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural group therapy (CBGT)
Trial: 15305399
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of epirubicin (90 mg/m2) and paclitaxel (200 mg/m2) for 8 cycles
Trial: 15305399
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of epirubicin (120 mg/m2 for 4 cycles) followed by paclitaxel (250 mg/m2 over 3 hours for 4 cycles)
Trial: 11453871
Drug: Vitamin E-modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin E-modified membrane (E) with Vitamin C infusion (C)
Trial: 11453871
Drug: Nonmodified cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmodified cellulose membrane (O) with Vitamin C infusion (C)
Trial: 2454128
Drug: 6% dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% dextran added to lignocaine solution containing adrenaline
Trial: 2454128
Drug: Lignocaine solution
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lignocaine solution containing adrenaline without dextran
Trial: 25212278
Drug: IMN (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMN (0.6 L/d)
Trial: 25486372
Drug: Cognitive-Behavior Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavior Therapy (CBT)
Trial: 19367116
Drug: Probiotics (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (various strains such as Bifidobacterium, Lactobacillus, and Lactococcus) administered during the perinatal period
Trial: 15110921
Drug: Hydrocortisone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (5 or 10 mg, p.o.)
Trial: 15110921
Drug: CRH stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH stimulation (1 g/kg i.v.)
Trial: 8463575
Drug: Mifepristone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (200 mg on days 1 and 2)
Trial: 2939218
Drug: Ketanserin (K),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (K), 40 mg/day
Trial: 2939218
Drug: Metoprolol (M),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (M), 200 mg/day
Trial: 20002596
Drug: Milnacipran 100
RxNorm normalized name: milnacipran 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 100 mg/day (re-randomized from placebo or milnacipran 100 mg/day)
Trial: 20002596
Drug: Milnacipran 200
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milnacipran 200 mg/day (for patients re-randomized from placebo)
Trial: 18754195
Drug: Ibuprofen-releasing foam
RxNorm normalized name: ibuprofen Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen-releasing foam dressing (Biatain Ibu, ColoplastA/S)
Trial: 15286005
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 mg/kg or 10 mg/kg every four or eight weeks)
Trial: 12799626
Drug: Darbepoetin alpha
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alpha QW (0.5, 1.0, 2.25, or 4.5 micro g kg(‐1) week(‐1) for 12 weeks)
Trial: 12799626
Drug: Darbepoetin alpha
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alpha Q3W (6.75 micro g kg(‐1) for 12 weeks)
Trial: 12799626
Drug: Darbepoetin alpha
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alpha Q4W (6.75 or 10.0 micro g kg(‐1) for 12 weeks)
Trial: 8195451
Drug: Clonazepam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (mean dose 2.2 mg, SD 0.7 mg)
Trial: 28328526
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (100,000 IU single oral dose)
Trial: 24034569
Drug: High-dose Asiatic
RxNorm normalized name: asiatic acid
DrugBank: Asiatic acid (DB14054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Asiatic plantain extract (20 g/80 mL)
Trial: 21964893
Drug: Bevacizumab containing
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab containing chemotherapy
Trial: 17052276
Drug: PEG‐IFN (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN (180 microg sc weekly) and standard dose of RBV (1000/1200 mg po daily, STD)
Trial: 17052276
Drug: PEG‐IFN (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN (180 microg sc weekly) and low‐dose of RBV (600/800 mg po daily, LOW)
Trial: 12588538
Drug: Investigational anticancer
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational anticancer drugs
Trial: 12588538
Drug: Earlier phases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earlier phases of investigational anticancer drugs
Trial: 8445198
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone given within 8 hours of spinal cord injury
Trial: 27209422
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) in the form of exposure and response prevention, 14 weekly sessions
Trial: 16520033
Drug: 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 every 6 weeks (ARM A)
Trial: 16520033
Drug: 50 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 every 4 weeks (ARM B)
Trial: 10714017
Drug: Nicorandil pretreatment
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil pretreatment (0.3 mg/kg) 30 minutes before aortic cross clamping
Trial: 8959996
Drug: Riluzole (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (any dose)
Trial: 25523190
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D therapy
Trial: 29533998
Drug: Depot vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot vitamin D therapy
Trial: 25782919
Drug: Ropivacaine (0.25%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (0.25%, 40 mL)
Trial: 25782919
Drug: Control (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.9% saline, 40 mL)
Trial: 24447501
Drug: Levosimendan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (6 μg/kg loading dose followed by 0.1 μg/kg/min infusion for 24 hours)
Trial: 25053182
Drug: Standard inotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inotropic therapy
Trial: 20150300
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of mild GDM during pregnancy
Trial: 11547841
Drug: Milk supplementation
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk supplementation (50 g of milk powder containing 800 mg of calcium per day)
Trial: 23998557
Drug: Propionyl-L-carnitine (PLC)
RxNorm normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine (PLC)
Trial: 31917621
Drug: Thrombomodulin alfa
RxNorm normalized name: Thrombomodulin Alfa
DrugBank: Thrombomodulin Alfa (DB05777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombomodulin alfa (380 U/kg/d for 14 days by intravenous drip infusion)
Trial: 17692438
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) route with 3, 6, or 9 microg of vaccine
Trial: 17692438
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) route with 15 microg of vaccine
Trial: 17692438
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) route
Trial: 12373440
Drug: 0.25 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g/kg alcohol
Trial: 12373440
Drug: 0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/kg alcohol
Trial: 28035589
Drug: Caspofungin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 100 mg loading dose followed by 50 mg maintenance dose for patients with total body weight of ≤80 kg
Trial: 28035589
Drug: Caspofungin 70
RxNorm normalized name: caspofungin 70 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 70 mg maintenance dose for patients with total body weight of >80 kg
Trial: 23375819
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 3 g/d
Trial: 23375819
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (0.5‐1 g/m²)
Trial: 21516030
Drug: tesamorelin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tesamorelin (2 mg subcutaneously daily for 26 weeks)
Trial: 21516030
Drug: placebo (subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (subcutaneously daily for 26 weeks)
Trial: 17279300
Drug: Ciprofloxacin 1
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day for 4 weeks
Trial: 17279300
Drug: Mesalamine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine (4 g/day oral, 8 g/day enema, or 1 g/day suppository)
Trial: 15484217
Drug: Low-dose suramin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose suramin
Trial: 15484217
Drug: Intermediate-dose suramin
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose suramin
Trial: 15484217
Drug: High-dose suramin
RxNorm normalized name: suramin
DrugBank: Suramin (DB04786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose suramin
Trial: 16689755
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups post-treatment
Trial: 8028755
Drug: carbocalcitonin +
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carbocalcitonin + arginine-lysine-lactose combination
Trial: 2653110
Drug: Testosterone-undecanoate 120
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone-undecanoate 120 mg per os for 100 days
Trial: 887645
Drug: 300 IU
RxNorm normalized name: Follistim AQ 300 IU per 0.36 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IU daily of synthetic oxytocin
Trial: 887645
Drug: 600 IU
RxNorm normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 IU daily of synthetic oxytocin
Trial: 31561192
Drug: Real-time medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time medication monitoring pill bottle linked to an HIV self-management app
Trial: 1445478
Drug: Loratadine 10
RxNorm normalized name: loratadine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 10 mg q.d.
Trial: 1445478
Drug: Hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 25 mg t.i.d.
Trial: 22048237
Drug: Selumetinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (100 mg orally twice daily in 28-day cycles)
Trial: 22048237
Drug: Temozolomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (200 mg/m2/day for 5 days, then 23 days off-treatment)
Trial: 1836986
Drug: Cilazapril 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 5.0 mg/day
Trial: 1836986
Drug: Cilazapril 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 10.0 mg/day
Trial: 30962603
Drug: Personalized information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized information treatments targeting parents' misbeliefs about their children's absences
Trial: 23592025
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TNA) 10 mg/kg administered intravenously 20 min before tourniquet deflation and repeated 3 h after surgery for unilateral TKA; an additional dose of TNA 10 mg/kg before tourniquet deflation for the second TKA in bilateral TKA patients.
Trial: 17216337
Drug: Aqua‐E (water-soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua‐E (water-soluble vitamin E formulation)
Trial: 14675055
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg orally for 10 days during LBNP
Trial: 3912093
Drug: Intravenous PGE1
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous PGE1 (15 micrograms/h for 72 h)
Trial: 31676660
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Group Therapy (CRGT) - combining mindfulness-based stress reduction with brain training activities